Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer

Radiation therapy is considered a standard treatment option for the management of localized prostate cancer. Among the 20-30% of patients who recur, there is no consensus on the optimal salvagetherapy. Salvage options available for isolated local recurrence include; temporary or permanent implantation of radioactive seeds into the prostate, complete removal of the prostate gland, use of low temperatures to treat the disease (cryotherapy), and high frequency ultrasound to treat the disease. There are risks of complications associated with all these treatments, and there is presently no consensus as to which treatment is the best. The aim of this pilot study is to look at the feasibility and toxicities of whole gland salvage treatment of the prostate using temporary implantation of radioactive seeds into the prostate.

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study

Intervention Model: Single Group Assignment

Masking: Open Label

Primary Purpose: Treatment

Official Title: Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer

Estimated Enrollment: 15

Study Start Date: August 2014

Estimated Study Completion Date: August 2019

Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)

Arms:

HDR whole gland salvage treatment
Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart